Recently we’ve been following the story of MyMD, particularly in regard to its lead drug indication – MYMD-1® – in Phase 2 trials for sarcopenia (aka aging). But what led MyMD to pursue this path?
As all companies have limited resources, Dr. Brager (Senior Executive Director of Regulatory Affairs for MyMD) overviews here how companies weigh the decision to take up a new drug indication. But the main question is, “Will the new drug be able to significantly challenge the current ‘gold standard’ treatment?”
In our “user-friendly’ report, we overviewed not 1 but 3 reasons how MYMD-1® has the potential to outperform the three Big Dog TNF-alpha inhibitors in this field.
Reason #1 was covered in a recent email (MYMD-1’s ability to be taken orally)…so here is Reason #2:
MYMD-1® is being positioned to treat brain-related disorders! 🧠🧠🧠
MYMD-1® is engineered in small molecule form. In small molecule form, it can cross the blood-brain barrier and gain access to the central nervous system.
“I am not a biologist,” you say?
That’s okay – as Dr. Kaplin (MyMD’s Chief Scientific Officer) explains here, essentially the blood brain barrier prevents substances that are harmful from entering the brain. However, it also keeps out beneficial medications that can treat brain-related disorders, including multiple sclerosis (MS) as well as depression in age or inflammatory-related diseases.
So this ability to cross the blood-brain barrier opens up all kinds of possibilities in treating brain-related disorders. And can the gold standards do this – NO! None of the leaders as identified in our report can cross the blood-brain barrier because they are in larger molecule form.
And if this doesn’t excite you, we’ll be sharing reason #3 with you in our next email – but if you can’t wait, check out our report here.
If the science doesn’t get you excited, then the price chart should! MYMD has defended a serious support level around $3.30 for over 2 weeks now.
Look at the key levels right now: